Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis

被引:3
|
作者
Kim, Hyejung [1 ]
Son, Ilhong [1 ,2 ]
Seol, Wongi [1 ]
机构
[1] Wonkwang Univ, InAm Neurosci Res Ctr, Sanbonro 321, Gunposi, Gyeonggido, South Korea
[2] Wonkwang Univ, Dept Neurol, Coll Med, Sanbon Med Ctr, Gunposi, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Protein synthesis; LRRK2; Parkinson's disease; G2019S; kinase; PARKINSONS-DISEASE; PHOSPHORYLATION; AUTOPHAGY; 4E-BP; P53;
D O I
10.1080/19768354.2017.1422803
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD) in an autosomal dominant manner. Pathogenic mutations of LRRK2 such as G2019S and R1441C have been observed as common genetic causes of PD. Recently, LRRK2 has been reported to increase the reporter protein synthesis in both cap-dependent and -independent manners via phosphorylation of the ribosomal protein RPS15. In this study, we tested whether LRRK2 recombinant protein would directly increase protein synthesis using a well-defined in vitro coupled transcription/translation system. Addition of commercial full-length LRRK2 or GST-fused N-terminal-deleted LRRK2 recombinant proteins to the system showed no change of protein synthesis, as measured by luciferase reporter activity. In addition, the SUnSET assay to measure newly synthesized cellular proteins showed that G2019S overexpression had a minimal effect on the total protein amount. However, we confirmed the previous result that G2019S overexpression increased the amount of protein synthesized from an exogenous gene, Flag-VAMP2, which was transfected as a reporter, whereas there was no significant change in the amount of the Flag-VAMP2 mRNA. Inhibition of protein degradation showed that protein accumulation in the vector control was higher than that of the G2019S overexpression vector. Our results suggest that LRRK2 protein influences the amount of protein by inhibiting protein degradation rather than by directly stimulating translation.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
  • [41] Targeting leucine-rich repeat kinase 2 in Parkinson's disease
    Chan, Sharon L.
    Angeles, Dario C.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) : 1471 - 1482
  • [42] A QUICK Screen for Lrrk2 Interaction Partners - Leucine-rich Repeat Kinase 2 is Involved in Actin Cytoskeleton Dynamics
    Meixner, Andrea
    Boldt, Karsten
    Van Troys, Marleen
    Askenazi, Manor
    Gloeckner, Christian J.
    Bauer, Matthias
    Marto, Jarrod A.
    Ampe, Christophe
    Kinkl, Norbert
    Ueffing, Marius
    MOLECULAR & CELLULAR PROTEOMICS, 2011, 10 (01)
  • [43] Interferon- induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages
    Kuss, Martin
    Adamopoulou, Eleni
    Kahle, Philipp J.
    JOURNAL OF NEUROCHEMISTRY, 2014, 129 (06) : 980 - 987
  • [44] Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2
    Shore, Daniel G. M.
    Sweeney, Zachary K.
    Beresford, Alan
    Chan, Bryan K.
    Chen, Huifen
    Drummond, Jason
    Gill, Andrew
    Kleinheinz, Tracy
    Liu, Xingrong
    Medhurst, Andrew D.
    McIver, Edward G.
    Moffat, John G.
    Zhu, Haitao
    Estrada, Anthony A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (04) : 674 - 680
  • [45] Leucine-Rich Repeat Kinase 2 (LRRK2) Stimulates IL-1β-Mediated Inflammatory Signaling through Phosphorylation of RCAN1
    Han, Kyung A.
    Yoo, Lang
    Sung, Jee Y.
    Chung, Sun A.
    Um, Ji W.
    Kim, Hyeyoung
    Seol, Wongi
    Chung, Kwang C.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2017, 11
  • [46] Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
    Estrada, Anthony A.
    Liu, Xingrong
    Baker-Glenn, Charles
    Beresford, Alan
    Burdick, Daniel J.
    Chambers, Mark
    Chan, Bryan K.
    Chen, Huifen
    Ding, Xiao
    Di Pasquale, Antonio G.
    Dominguez, Sara L.
    Dotson, Jennafer
    Drummond, Jason
    Flagella, Michael
    Flynn, Sean
    Fuji, Reina
    Gill, Andrew
    Gunzner-Toste, Janet
    Harris, Seth F.
    Heffron, Timothy P.
    Kleinheinz, Tracy
    Lee, Donna W.
    Le Pichon, Claire E.
    Lyssikatos, Joseph P.
    Medhurst, Andrew D.
    Moffat, John G.
    Mukund, Susmith
    Nash, Kevin
    Scearce-Levie, Kimberly
    Sheng, Zejuan
    Shore, Daniel G.
    Thuy Tran
    Trivedi, Naimisha
    Wang, Shumei
    Zhang, Shuo
    Zhang, Xiaolin
    Zhao, Guiling
    Zhu, Haitao
    Sweeney, Zachary K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9416 - 9433
  • [47] A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls
    Vissers, Maurits F. J. M.
    Troyer, Matthew D.
    Thijssen, Eva
    Heuberger, Jules A. A. C.
    Groeneveld, Geert Jan
    Huntwork-Rodriguez, Sarah
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (08): : 1408 - 1420
  • [48] The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation
    Hassin-Baer, Sharon
    Laitman, Yael
    Azizi, Esther
    Molchadski, Irena
    Galore-Haskel, Gilli
    Barak, Frida
    Cohen, Oren S.
    Friedman, Eitan
    JOURNAL OF NEUROLOGY, 2009, 256 (03) : 483 - 487
  • [49] Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism
    Chen, Kang
    Tang, Fei
    Du, Bin
    Yue, Zhe-Zhou
    Jiao, Ling-Ling
    Ding, Xu-Long
    Tuo, Qing-Zhang
    Meng, Jie
    He, Si-Yu
    Dai, Lunzhi
    Lei, Peng
    Wei, Xia-Wei
    MEDCOMM, 2023, 4 (06):
  • [50] Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease
    Huang, Liang
    Shimoji, Mika
    Wang, Juan
    Shah, Salim
    Kamila, Sukanta
    Biehl, Edward R.
    Lim, Seung
    Chang, Allison
    Maguire-Zeiss, Kathleen A.
    Su, Xiaomin
    Federoff, Howard J.
    NEUROTHERAPEUTICS, 2013, 10 (04) : 840 - 851